300 related articles for article (PubMed ID: 30155928)
41. [Molecular subgrouping and characterization analysis of medulloblastomas in a cohort of Japanese patients].
Wataya T; Hamasaki M; Taylor MD
No Shinkei Geka; 2015 Feb; 43(2):117-25. PubMed ID: 25672552
[TBL] [Abstract][Full Text] [Related]
42. ASPM gene expression in medulloblastoma.
Vulcani-Freitas TM; Saba-Silva N; Cappellano A; Cavalheiro S; Marie SK; Oba-Shinjo SM; Malheiros SM; de Toledo SR
Childs Nerv Syst; 2011 Jan; 27(1):71-4. PubMed ID: 20694558
[TBL] [Abstract][Full Text] [Related]
43. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.
Hill RM; Richardson S; Schwalbe EC; Hicks D; Lindsey JC; Crosier S; Rafiee G; Grabovska Y; Wharton SB; Jacques TS; Michalski A; Joshi A; Pizer B; Williamson D; Bailey S; Clifford SC
Lancet Child Adolesc Health; 2020 Dec; 4(12):865-874. PubMed ID: 33222802
[TBL] [Abstract][Full Text] [Related]
44. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
Wang Y; Huang J; Yin X; Xu Q; Sun Y; Yao Y; Xiong J
Acta Neurochir (Wien); 2024 Feb; 166(1):72. PubMed ID: 38329556
[TBL] [Abstract][Full Text] [Related]
45. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Tarasińska M; Perek-Polnik M; Krętowski A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Matyja E
Am J Surg Pathol; 2017 Jun; 41(6):781-787. PubMed ID: 28338501
[TBL] [Abstract][Full Text] [Related]
46. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
Moreno DA; da Silva LS; Zanon MF; Bonatelli M; de Paula FE; de Medeiros Matsushita M; Teixeira GR; Santana IVV; Saggioro F; Neder L; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Garcia-Rivello H; Christiansen S; Nunes S; da Costa MJG; Soares MJ; Pinheiro J; Junior CA; Mançano BM; Reis RM
J Neurooncol; 2022 Mar; 157(1):27-35. PubMed ID: 35166989
[TBL] [Abstract][Full Text] [Related]
47. Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.
Friedrich C; Shalaby T; Oehler C; Pruschy M; Seifert B; Picard D; Remke M; Warmuth-Metz M; Kortmann RD; Rutkowski S; Grotzer MA; von Bueren AO
Childs Nerv Syst; 2017 Sep; 33(9):1463-1471. PubMed ID: 28695340
[TBL] [Abstract][Full Text] [Related]
48. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
[TBL] [Abstract][Full Text] [Related]
49. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
50. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
51. Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature.
Siegfried A; Bertozzi AI; Bourdeaut F; Sevely A; Loukh N; Grison C; Miquel C; Lafon D; Sevenet N; Pietsch T; Dufour C; Delisle MB
Clin Neuropathol; 2016; 35(3):106-13. PubMed ID: 26857864
[TBL] [Abstract][Full Text] [Related]
52. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
53. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
54. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.
Banfield E; Brown AL; Peckham EC; Rednam SP; Murray J; Okcu MF; Mitchell LE; Chintagumpala MM; Lau CC; Scheurer ME; Lupo PJ
Cancer Epidemiol; 2016 Oct; 44():161-166. PubMed ID: 27607585
[TBL] [Abstract][Full Text] [Related]
55. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma.
Raso A; Mascelli S; Biassoni R; Nozza P; Kool M; Pistorio A; Ugolotti E; Milanaccio C; Pignatelli S; Ferraro M; Pavanello M; Ravegnani M; Cama A; Garrè ML; Capra V
Neuro Oncol; 2011 May; 13(5):500-8. PubMed ID: 21486962
[TBL] [Abstract][Full Text] [Related]
56. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
Priller M; Pöschl J; Abrão L; von Bueren AO; Cho YJ; Rutkowski S; Kretzschmar HA; Schüller U
Clin Cancer Res; 2011 Nov; 17(21):6791-801. PubMed ID: 21918172
[TBL] [Abstract][Full Text] [Related]
57. Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage.
Reisinger D; Gojo J; Kasprian G; Haberler C; Peyrl A; Azizi AA; Mayr L; Chocholous M; Kool M; Czech T; Slavc I
Neurosurgery; 2020 Apr; 86(4):478-484. PubMed ID: 31065705
[TBL] [Abstract][Full Text] [Related]
58. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker.
Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Schrimpf D; Ghasemi DR; Pajtler KW; Antonelli M; Donofrio V; Mastronuzzi A; Rossi S; Camassei FD; Buccoliero AM; Haberler C; Slavc I; Dahiya S; Casalini B; Sievers P; Meyer J; Kumirova E; Zheludkova O; Golanov A; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2020 Mar; 139(3):583-596. PubMed ID: 31781912
[TBL] [Abstract][Full Text] [Related]
59. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
60. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
